Brookline Capital Markets analyst Leah R. Cann maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) today and set a price target of $93.00. The company’s shares opened today at $27.87.
According to TipRanks, R. Cann is a 2-star analyst with an average return of 0.1% and a 39.93% success rate. R. Cann covers the Healthcare sector, focusing on stocks such as Moderna, Kymera Therapeutics, and SQZ Biotechnologies.
Kymera Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $56.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $69.12 and a one-year low of $13.15. Currently, Kymera Therapeutics has an average volume of 724.9K.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of KYMR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera’s Pegasus targeted protein degradation platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade the intractable of proteins, and advance new treatment options for patients.
Read More on KYMR:
- Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Cutaneous T-Cell Lymphoma
- Kymera Therapeutics to Participate in Upcoming September Conferences
- Kymera Announces $150 Million Private Placement Equity Financing
- Kymera Therapeutics Announces Second Quarter 2022 Financial Results and Provides a Business Update
- Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
